Genistein reduces the production of proinflammatory molecules in human chondrocytes

YKL-40: a potential biomarker for osteoarthritis

Current pharmacotherapy for osteoarthritis (OA) alleviates pain and inflammation but does not protect the articular cartilage from further damage or affect disease progression. Biological markers such as YKL-40 may provide a snapshot of current events in joint tissues, allowing rapid assessment of treatments. This review discusses recent data regarding YKL-40, with an emphasis on the relationship between YKL-40 and OA. The presence of YKL-40 in cartilage and synovium in OA patients correlates with histopathological changes and may reflect local disease activity. In addition, the levels of YKL-40 in serum and synovial fluid also seem to correlate with disease severity. The functional role of YKL-40 is not yet clear, but its production as part of the inflammatory response in articular chondrocytes may modulate the cellular response to proinflammatory cytokines, acting to limit connective tissue degradation. Further elucidation of its roles and relationships may enable YKL-40 to act as a useful biomarker in the development of therapies for OA.

Bioactive food components, inflammatory targets, and cancer prevention

Various dietary components may modify chronic inflammatory processes at the stage of cytokine production, amplification of nuclear factor-kappaB-mediated inflammatory gene expression, and the release of anti-inflammatory cytokine, transforming growth factor-beta. This review provides a synopsis of the strengths and weaknesses of the evidence that specific bioactive food components influence inflammation-related targets linked to cancer. A target repeatedly surfacing as a site of action for several dietary components is transforming growth factor beta. Whereas the use of dietary intervention strategies offers intriguing possibilities for maintaining normal cell function by modifying a process that is essential for cancer development and progression, more information is needed to characterize the minimum quantity of the bioactive food components required to bring about a change in inflammation-mediated cancer, the ideal time for intervention, and the importance of genetics in determining the response. Unquestionably, the societal benefits of using foods and their components to prevent chronic inflammation and associated complications, including cancer, are enormous.

Inflammation and prostate cancer

Prostate cancer remains a major health concern for the male population throughout the Western world. It is today widely accepted that inflammation has a role in many human cancers. In fact, inflammation is thought to incite carcinogenesis by causing cell and genome damage, promoting cellular turnover and creating a tissue microenvironment that can enhance cell replication, angiogenesis and tissue repair. Accordingly, there is a body of literature suggesting a link between chronic inflammation and prostate cancer, in which prostate inflammation may contribute to the promotion of prostate cancer development. On the other hand, high levels of endogenous gonadal steroids are considered as risk factors for prostate cancer. Interestingly, it is clear that elevation of estrogens in the presence of testosterone results in a prostate-specific inflammatory response. Thus, it is possible that early inflammatory events stimulated by sex hormones serve as a prerequisite for the onset of prostate cancer.

Bowman-Birk inhibitor and genistein among soy compounds that synergistically inhibit nitric oxide and prostaglandin E2 pathways in lipopolysaccharide-induced macrophages

Inflammation has an important role in the development of chronic diseases. In this study, we evaluated the anti-inflammatory properties of eight soybean bioactive compounds using lipopolysaccharide-induced RAW 264.7 macrophages. Genistein, daidzein, a mix of isoflavone glucosides, saponin A group glycosides (saponin A), saponin B group glycosides (saponin B), sapogenol B, Bowman-Birk inhibitor (BBI), lunasin, and pepsin-pancreatin glycinin hydrolysates were tested by measuring their ability to inhibit cyclooxygenase-2/prostaglandin E(2) (PGE(2)) and inducible nitric oxide synthase (iNOS)/nitric oxide (NO) inflammatory pathways. Of the eight soy bioactive compounds (SBCs) tested, BBI and sapogenol B resulted in the highest inhibition of pro-inflammatory responses at a concentration 10 times lower than the one used for the other compounds. Also, sapogenol B and genistein (molar ratio 1:1) synergistically inhibited NO and additively inhibited PGE(2). Saponin A group glycosides showed inhibition of the iNOS/NO pathway only, while pepsin-pancreatin glycinin hydrolysates enhanced induction and production of the four inflammatory responses. For the first time, synergistic interactions were observed between BBI and genistein inhibiting NO (92.7%) and PGE(2) (95.6%) production. An antagonistic interaction was observed between the saponin B group glycosides and sapogenol B. All interactions were further confirmed by isobolographic analysis. These findings demonstrated that some SBCs possess anti-inflammatory properties and therefore are important in modulating mammalian inflammation pathways which may lead to inhibition of some types of chronic disease. Furthermore, through their interaction they can modulate the inflammatory process.

Biotechnology of flavonoids and other phenylpropanoid-derived natural products. Part I: Chemical diversity, impacts on plant biology and human health

Plant natural products derived from phenylalanine and the phenylpropanoid pathway are impressive in their chemical diversity and are the result of plant evolution, which has selected for the acquisition of large repertoires of pigments, structural and defensive compounds, all derived from a phenylpropanoid backbone via the plant-specific phenylpropanoid pathway. These compounds are important in plant growth, development and responses to environmental stresses and thus can have large impacts on agricultural productivity. While plant-based medicines containing phenylpropanoid-derived active components have long been used by humans, the benefits of specific flavonoids and other phenylpropanoid-derived compounds to human health and their potential for long-term health benefits have been only recognized more recently. In this part of the review, we discuss the diversity and biosynthetic origins of phenylpropanoids and particularly of the flavonoid and stilbenoid natural products. We then review data pertaining to the modes of action and biological properties of these compounds, referring on their effects on human health and physiology and their roles as plant defense and antimicrobial compounds. This review continues in Part II discussing the use of biotechnological tools targeting the rational reconstruction of multienzyme pathways in order to modify the production of such compounds in plants and model microbial systems for the benefit of agriculture and forestry.